FDA Approves New Formulation of Gvoke for Severe Hypoglycemia
The FDA has approved the new Gvoke® Kit formulation for the treatment of severe hypoglycemia in patients with diabetes 2 years of age and older.
The FDA has approved the new Gvoke® Kit formulation for the treatment of severe hypoglycemia in patients with diabetes 2 years of age and older.
Investigators studied whether adjusting insulin dose and timing for people with type 1 diabetes before certain meals could improve glycemic control.
Study authors conducted a retrospective cohort study to compare CSII and MDI treatments on metabolic control, body mass index, and prevalence of severe hypoglycemia in children.
The researchers hypothesized that as the participants became older adults, their cognitive functioning would decline more steeply relative to earlier assessments.
The product should be stored in a refrigerator but can be kept at room temperature for up to 12 months.
This retrospective cohort study assessed hospitalized patients with diabetes to see if the new ISF-based scales improved glycemic control vs a traditional single sliding scale.
The researchers’ objective was to evaluate the safety and efficacy of dasiglucagon in patients aged 6 to 17 years with type 1 diabetes.
An international team of investigators sought to assess outcomes with real-time continuous glucose monitoring to manage glycemic control in preterm infants.
Previous studies have shown that continuous subcutaneous insulin infusions can lead to improvements in clinical and quality of life benefits as compared to multiple daily injections of insulin. In this study, researchers led by Sanjeev Mehta, MD, MPH, of the Joslin Diabetes Center at Harvard University, test that concept in type 1 diabetes patients.
Study authors examined the risk of ED visits or hospitalizations for hypoglycemia among patients older than 65 who were initiated on glargine, detemir, or NPH insulin.